This could probably raise false negative and false positive rates, since recent reports validated that PIK3CA mutational status in breast cancer differed approximately 18% of the time between primary tumors and corresponding metastatic disease with changes in both directions (wild type to mutant type, and vice versa) [12, 13]. This evidence concerns the gene PIK3CA and breast cancer.